What the FDA labels say about taking them together
Bupropion and cyclobenzaprine
Cyclobenzaprine's FDA label of February 21, 2025 names bupropion in its warnings section; the bupropion labels PlainMeds reads (4) do not name cyclobenzaprine. The cyclobenzaprine label: “… reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), tramadol, bupropion, meperidine, verapamil, or MAO inhibitors.”
Check it at the source: the bupropion FDA label on DailyMed (effective June 21, 2024); the cyclobenzaprine FDA label on DailyMed (effective February 21, 2025, Jubilant Cadista Pharmaceuticals Inc.).
What does the bupropion label say about cyclobenzaprine?
Bupropion's label (effective June 21, 2024) and its 3 other brand-application labels do not name cyclobenzaprine in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (BUPROPION HYDROCHLORIDE), Epic Pharma LLC, effective June 21, 2024 (SPL set 9fb44e96-6160-4a4a-90cb-91764c0dcd89), via openFDA; the full label on DailyMed
What does the cyclobenzaprine label say about bupropion?
Cyclobenzaprine label, warningsWARNINGS Serotonin Syndrome The development of a potentially life-threatening serotonin syndrome has been reported with cyclobenzaprine hydrochloride when used in combination with other drugs, such as selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), tramadol, bupropion, meperidine, verapamil, or MAO inhibitors.
Cyclobenzaprine Hydrochloride label (Teva Pharmaceuticals USA, Inc., May 31, 2024), drug interactionsPostmarketing cases of serotonin syndrome have been reported during combined use of cyclobenzaprine and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors [see Warnings and Precautions ( 5.1 )].
Tonmya label (Tonix Medicines, Inc., August 14, 2026), drug interactionsPostmarketing cases of serotonin syndrome have been reported with the concomitant use of oral cyclobenzaprine and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors [see Warnings and Precautions (5.2) ].
Source: FDA drug label (Cyclobenzaprine Hydrochloride, NDA021777), Teva Pharmaceuticals USA, Inc., effective May 31, 2024 (SPL set ca74d27a-f7c6-462d-a913-1cfa061bd8f3), via openFDA
Source: FDA drug label (Tonmya, NDA219428), Tonix Medicines, Inc., effective August 14, 2026 (SPL set 6fa59588-ce9b-48cf-8c5f-725a448f8571), via openFDA
Source: FDA drug label (Cyclobenzaprine Hydrochloride), Jubilant Cadista Pharmaceuticals Inc., effective February 21, 2025 (SPL set 592871f6-0eb2-4624-9e10-bd8bf767c002), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Bupropion | Cyclobenzaprine | |
|---|---|---|
| Labeled for | Depression, Quitting smoking | Muscle spasms and spasticity, Nerve pain and fibromyalgia |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.0785 per tablet 150 mg tablet | $0.0171 per tablet 10 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once